Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib Monotherapy in Newly Diagnosed Japanese CP CML
NCT03128411Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosutinib in chronic myeloid leukemia (CML), sponsored by Pfizer. Primary endpoint: Major Molecular Response at 12 months. Started May 2017; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03128411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03128411.